Navigation Links
Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia

Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through

2016, According to a New Report from Decision Resources

WALTHAM, Mass., April 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia. Clinical data and expert opinion show that Bayer/Schering-Plough/Shionogi's Avelox (moxifloxacin) is similar in overall clinical efficacy to the market leader levofloxacin -- Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit. However, Avelox's advantages in bacteriological efficacy, spectrum of activity, and activity against key antibiotic-resistant pathogens earn the agent gold standard status for community acquired pneumonia.

The new report entitled Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists finds that, through 2016, there are no therapies in development that will displace Avelox as the clinical gold standard for the treatment of community-acquired pneumonia. Although levofloxacin is superior to Avelox in the areas of safety and delivery -- offering a lower incidence of dermatological reactions and a five-day course of treatment -- Avelox outperforms levofloxacin on efficacy measures such as bacteriological eradication and activity against penicillin-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus.

"Based on available data and expert opinion, we do not expect any therapy under development for community-acquired pneumonia to displace Avelox as the clinical gold standard for this indication through 2016," said John Lebbos, M.D. director at Decision Resources. "While some therapies in development for community-acquired pneumonia hold promise, most of them have efficacy, safety and/or delivery features that are inferior when compared with Avelox."

About the Report

Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
2. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
3. Creative work has health advantages, Population Research Center study shows
4. Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes
5. New Celebrity Introduces Students to Need, Advantages of Health Care Careers
6. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
7. MRI before surgery leads to better-adapted treatment for breast cancer
8. Obese women disadvantaged in both breast cancer treatment and diagnosis
9. Alcons PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
10. Extra Drug Improves Rectal Cancer Treatment
11. Combining liver cancer treatments doubles survival rates, UVA researchers find
Post Your Comments:
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ... company, Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. ... organic facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says ...
(Date:11/29/2015)... ... 2015 , ... NewsWatch featured X-wing as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the future because flying cars are about to become a reality. Where’s the idea ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion from ... designed specially for Final Cut Pro X. FCPX users can now ... modification controls. Destoying and creating chaotic distortion is now quick and simple, putting ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Safe storage ... creativity of two inventors, one from Lakewood, New Jersey and the other from Bradley ... the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing all ... year? , This question has not been an easy question to answer. Especially when ... and the younger workforce don’t share the same discipline around working long hours. ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... -- The GE Health Cloud 1 was unveiled today at ... North America (RSNA) meeting in Chicago ... cloud ecosystem and its applications will connect radiologists and clinicians ... teams – both inside and outside the hospital setting. ... "As the digital industrial leader, we are betting big on ...
(Date:11/27/2015)... Une nouvelle approche consistant ... contre le cancer avancé.    --> ... au traitement photodynamique au Bremachlorin contre le cancer ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    Clinical Cancer Research . ...
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
Breaking Medicine Technology: